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Abstract
Background: The regulation of the markets for Complementary and Alternative Medicine (CAM) products presents
a global challenge. There is a dearth of studies that have examined or evaluated the regulatory policies of CAM
products in the Eastern Mediterranean Region (EMR). We investigate the regulatory frameworks and the barriers for
the proper regulation and integration of CAM products in Lebanon, as an example of an EMR country with a weak
public infrastructure.
Methods: We utilized a qualitative study design involving a series of semi-structured interviews with stakeholders
of the CAM market in Lebanon. Snowball sampling was used to identify interviewees; interviews continued until
the “saturation” point was reached. A total of 16 interviews were carried out with decision makers, representatives
of professional associations, academic researchers, CAM product importers, policy makers and a media
representative. Interviews were transcribed and thematic analysis of scripts was carried out.
Results: There was a consensus among all stakeholders that the regulation of the market for CAM products in
Lebanon needs to be strengthened. Thematic analysis identified a number of impediments jeopardizing the safety
of public consumption and hindering the integration of CAM therapies into mainstream medicine; including: weak
infrastructure, poor regulation, ineffective policies and politics, weak CAM awareness and sub-optimal coordination
and cooperation among stakeholders. With respect to policy instruments, voluntary instruments (self regulation)
were deemed ineffective by stakeholders due to poor awareness of both users and providers on safe use of CAM
products. Stakeholders’ rather recommended the adoption of a combination of mixed (enhancing public
awareness and integration of CAM into medical and nursing curricula) and compulsory (stricter governmental
regulation) policy instruments for the regulation of the market for CAM products.
Conclusions: The current status quo with respect to the regulation of CAM products in Lebanon is not conducive
to public safety, nor does it support the integration of CAM products into the healthcare system. The Ministry of
Health indeed plays a dominant role in the regulation of these products through a combination of mixed and
compulsory policy instruments. Yet, the proper implementation of these regulations requires political resolve
coupled with the cooperation of all CAM stakeholders.
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Complementary and Alternative Medicine (CAM) are a
diverse group of medical and healthcare systems, prac-
tices and products that are not considered part of con-
ventional medicine, yet complement it by diversifying
t h ec o n c e p t u a lf r a m e w o r k so fm e d i c i n eo rb ys a t i s f y i n g
a demand not met by orthodoxy [1,2]. The US National
Center for CAM therapies divides CAM into four cate-
gories: (1) Mind-body systems; (2) Manipulative and
body-based practices; (3) Energy Medicine; and (4) Bio-
logically based practices [1]. In this manuscript, CAM
refers to biologically based practices including sub-
stances found in nature, such as herbs, dietary supple-
ments, multivitamin and mineral supplements [1,3]. The
increasing popularity and usage of CAM products has
precipitated regulatory challenges for many countries
across the globe [4-11]. In Lebanon, the number of
CAM products introduced into the market grew steadily
since 1980. In 2003, the total number of CAM products
in the Lebanese market was estimated at around 1,300
[12]. Recent estimates indicate that the number of CAM
products has exceeded 3000. Amid the increased popu-
larity of CAM products and the growing size of their
market [13,14], there is a dearth of systematic studies
investigating the regulatory framework for CAM pro-
ducts and the barriers towards their proper integration
into the healthcare system in the Eastern Mediterranean
Region (EMR).
The argument for regulation
Regulation of CAM products is geared towards ensuring
quality standards and enhancing consumers’ safety [15].
Without proper regulation, CAM users could be sub-
jected to various degrees of risks ranging from inap-
propriate use to serious life threatening adverse events
[16]. Various jurisdictions have reported an issue with
the labeling and advertising of CAM products; false
claims of a ‘magic treatment’ are not uncommon [17].
Governmental interventions are necessary to protect
customers against false and misleading claims; possible
manipulation of safety test results; substandard manu-
facturing processes and substitution of ingredients [18].
Although the majority of CAM products may not
carry any side effects to consumers, advertised false
claims could cause consumers to modify or stop the use
of essential prescribed medications without proper med-
ical advice. This jeopardizes the safety of consumers and
places a serious mandate on governments to lead a reg-
ulatory agenda. Furthermore, acute or chronic overdose
has been reported in individuals falsely believing that
increased consumption of the ‘All Natural’ CAM pro-
ducts will enhance their acclaimed benefits and lead to
faster recovery or relief [19]. Proper regulation is also
necessary to protect against biological interactions
between CAM products or between CAM products and
pharmaceuticals [19].
Note that the cost of CAM products in the EMR is
usually covered out of pocket, since private or social
insurance programs do not cover such costs. Therefore,
improper utilization of CAM products could cause a
financial burden on the stretched resources of poor and
middle income families. Furthermore, using CAM pro-
ducts could delay the use of orthodox medicine which
increases the burden of disease on governments or indi-
viduals, who might incur greater costs to cure once
easy-to-manage diseases [19]. In conclusion, in the
absence of regulation the use of CAM products may
harm consumer either directly through adverse events,
or indirectly by creating an unwarranted financial and
emotional burden on users [20].
Governmental regulation is pivotal to protect against
these harms and could facilitate the integration of CAM
products into modern healthcare systems. While regula-
tion of the CAM market presents a challenge for many
countries across the globe, regulation is particularly
challenging in countries with a weak public sector; such
as Lebanon [21]. Regulatory policy instruments, at the
discretion of governments, can be arranged along a scale
depending on the degree of ‘legitimate coercion’
involved [22]. According to Doern and Phidd (1992), at
one end of this scale are voluntary instrument, the least
coercive of which is ‘self regulation’; while at the other
end lies compulsory instruments, the most coercive of
which is the complete ‘public ownership’ of markets or
resources. In between the two extremes lie a number of
mixed policy instruments involving various degrees of
public and private regulation, including: public educa-
tion, subsidization and product taxation [22].
CAM regulation and integration: a global challenge
A plethora of factors make CAM regulation and integra-
tion a global challenge. These factors include absence of
guidelines for CAM practice, insufficient research to
prove cost-effectiveness and the limited commitment of
insurers for reimbursement [23,24]. Other challenges
related to CAM providers include: ignorance about
CAM, lack of licensing for CAM professionals, fear and
resistance to change by medical establishment, lack of
data on usage of CAM, lack of provider networks, as
well as lack of coordination and communication
between CAM providers and the existing health systems
[24,25].
In its global survey report on national policies on tra-
ditional medicine and regulation of herbal medicines,
WHO stated that the major challenges are related to
“regulatory status, assessment of safety and efficacy,
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about TM/CAM” [26].
CAM products regulation in the Eastern Mediterranean
Region
Although the Eastern Mediterranean Region hosts one
of the fastest growing markets of CAM products in the
world [27], little is known about the use of CAM pro-
ducts in the region, except for a number of sporadic
reports that have examined specific patient populations
[28,29] or shy attempts to examine prevalence of use in
the Arabian Gulf region [30,31]. In addition, little is
published with respect to the regulation of CAM pro-
ducts in these countries.
CAM regulation in Lebanon
In lights of the growing market for CAM products in
Lebanon, the Lebanese Ministry of Health (MOH)
assigned an expert committee that was responsible for
regulating the entry of CAM products into the Lebanese
market. The committee received approval from the cabi-
net of Ministers in 1998 (decree number 11710). The
committee, led by the Director General of the MOH,
includes seven members from the trade, education and
research communities. The recommendations of this
committee receive final approval from the Minister of
Health.
The mandate of the expert committee included the
assessment of requests presented to the MOH for the
import, distribution and marketing of CAM products.
For example imported CAM products have to be certi-
fied for sales by the concerned ministries in their coun-
try of origin (free sales certificate) and should present a
Good Manufacturing Practice (GMP)-certificate sum-
marizing the content of the manufacturing license. The
companies should further present a detailed description
of constituents and a copy of the package label for each
of the products to be reviewed & approved prior to
entry into the Lebanese market. In the absence of this
review and approval process, products are prohibited
from the entry into the Lebanese market and their sale
is considered illegal. An illustration of the CAM review
process in Lebanon is presented in Figure 1.
In contrast to CAM, OTC products in Lebanon are
dealt with as pharmaceutical products and are thus sub-
jected to a much more stringent review and approval
processes. In addition to the requirements stated for
CAM products, the certification and review process for
OTC products requires importers to present a certificate
of pharmaceutical product, data on purchasing price and
public price, certificate of analysis and stability data.
OTC importers should also present a complete technical
file, including information on the product’sp h a r m a c o l -
ogy, physiochemical properties, bioavailability, terato-
genicity, inhibility tests for antibiotics, sterility and
progenicity, clinical studies and an extensive supportive
biography.
Despite the fast and steady growth of the number of
CAM products and outlets in Lebanon and amid a
growing public rhetoric on absent or ineffective regula-
tion of this market, our literature search reveals a dearth
of studies that have examined the regulatory policies of
CAM products and their implementation in the EMR
countries, in general, and Lebanon in particular.
Objectives
This study aims at soliciting the feedback of stake-
holders on the barriers for the proper regulation and
integration of CAM products in the Lebanese healthcare
system.
Figure 1 The CAM Review Process in Lebanon.
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Ethical approval
The proposal, interview schedule and consent form for
this study was reviewed and approved by the Institu-
tional Review Board at the American University of
Beirut.
Study design
We utilized a qualitative study design carrying out a ser-
ies of key informant interviews with stakeholders of the
CAM market in Lebanon. Well-conducted key infor-
mant interviews can provide a desirable combination of
objectivity and depth and often generate valuable data
that could not be successfully obtained by another
approach. Interviews can further allow for diverse per-
spectives on the events and fill in any documentation
gaps [32].
Selection of interviewees
In the choice of interviewees, we aimed at investigating
the different roles and perspectives of the multiple sta-
keholders in the CAM field. Interviewees in this study
included decision makers, representatives of professional
associations (Heads of orders and syndicates), academic
researchers (senior academicians from faculties of
agriculture, nutrition and pharmacy), CAM product
importers (owners or companies and CAM product
importers), policy makers (senior managers at the Min-
istry of Health and Ministry of Trade) and a media
representative (a public figure familiar with the field). A
more detailed matrix of the interviewees, showing the
background of each of the stakeholders, is presented in
Figure 2.
Interview schedule
A semi-structured interview schedule of ten questions
was utilized for data collection in this study. The inter-
view schedule was developed by the research team to
investigate the types of CAM products available in the
market in Lebanon, the regulatory frameworks in place
and the ways through which they can be enhanced, and
the barriers to the integration of CAM products into the
Lebanese Health Care system. Interviewees were further
asked to share with the research team any relevant
documents and to suggest the names of other stake-
holders that could contribute to this study.
Data collection
A number of key stakeholders (an academic, policy
maker, importer and a representative of a professional
ACADEMICS 
CAM6.  Herbal Medicine 
CAM12. Agriculture and food 
sciences  
CAM9. Pharmacology 
DECISION MAKERS  
 
CAM2. Nutrition/ Agriculture 
CAM3. Laboratory 
CAM11. Medicine 
 
POLICY MAKERS 
CAM4. CAM product licensure 
CAM15. Ministry of Health 
MEDIA 
CAM13. A leading media figure 
with experience in nutrition    
IMPORTERS/DISTRIBUTORS 
CAM8. European & American 
products 
CAM14. Products of various 
origins 
CAM16. Leading brand manager 
PROFESSIONAL ASSOCIATIONS  
CAM1. Consumer protection 
CAM5. Pharmacists  
 CAM7. Physicians  
CAM10. Consumer protection 
 
STAKEHOLDERS  
Figure 2 Distribution of Stakeholders by type and background.
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cipate in the study. Snowball sampling was subsequently
used to identify additional stakeholders. This process of
interviewing was continued until the “saturation” point
was reached; i.e., until no new information altered the
results already obtained and the names identified by
interviewees for additional interviews were repeated
[33].
All key informants were sent a standard email explain-
ing the objectives of the study and inviting them to a
personal interview. The consent form and the interview
schedule, approved by the American University of Beirut
Institutional Review Board (ethics), were attached to the
invitation. When potential interviewees did not respond
to the email within one week, the research team fol-
lowed up with a phone call. Overall, 16 out of a total 19
key informants accepted the invitation to an interview
and signed the consent form (84.2%). The three key
informants that did not accept to be interviewed apolo-
gized due to their busy work/travel schedule.
All interviews were conducted in the spring of 2010.
Interviews lasted an average of one hour. At the begin-
ning of each interview, interviewees were asked to sign
the consent form, which also included details about
their rights as participants in this research and acquired
their approval for tape recording the interviews. All
interviews, but one, were tape recorded. Along with tape
recording, the interviewers took field notes to facilitate
data analysis and provide a backup for important find-
ings in case certain data elements were missed during
the taping of interviews.
Data analysis
Thematic analysis was utilized in analyzing the data col-
lected from the key informant interviews. In thematic
analysis, researchers seeks themes that emerge from the
interview narratives through an ongoing process that
requires them to detect recurring issues and patterns
from the data rather than from predetermined codes
[34-36].
The interview tapes were then transcribed by the
research team. The transcripts provided an accurate
text of the interviews with “XXX” placed whenever the
discussion was not clear and capital letters to empha-
size intensity of certain points. Each transcript was
first read thoroughly by two members of the research
team. Initial readings of the scripts were meant to gain
a ‘primary feeling’ of the text and a general insight
into the answers of the interviewees. As a first step,
each of the questions of the interview script was used
as a broad theme and the answers of the interviewees
were classified under it. The statements that did not fit
under any of these questions were allocated to a theme
titled ‘miscellaneous’.
After the primary coding of all transcripts, analysis
sheets were re-coded into comprehensive broad themes
and subthemes by the two members of the research
team. Any coding disagreements between the two were
resolved in a series of research meetings until a final list
of sub-themes were generated. The final analysis sheet
included the newly formulated broad themes and their
corresponding subthemes. Relevant quotes were collated
under the various themes/sub-themes. All the members
of the research team reviewed and approved of the final
list of themes and sub-themes.
Results
Data analysis of stakeholders’ interviews identified three
overarching themes (and twelve associated sub-themes)
describing the market for CAM products in Lebanon,
current regulatory mechanisms and obstacles to proper
regulation/integration. These three themes were: Market
characterization, critique of current regulation and bar-
riers to proper regulation/integration. They are dis-
cussed below, along with their respective sub-themes, in
further details.
Market characterization
Key informants’ characterization of the market for CAM
products in Lebanon was listed under the theme of
“Market Characterization”. This theme included a gen-
eral description of the market and associated forces
shaping products’ supply and demand. Sub-themes
included: CAM products’ database, supply challenges,
common categories and triggers of consumptions of
CAM products.
There was a consensus among interviewees that it is
difficult to produce a comprehensive database of all the
products available in the Lebanese market. This could
be attributed to several supply challenges including: the
large number of CAM products that already exist at
Lebanese market and the loop holes in the system that
allow the entry of CAM products through a diversity of
official and unofficial channels that are beyond the con-
trol of the Ministry of Health (MOH).
With respect to CAM products’ categorization, inter-
views revealed that CAM products in the Lebanese mar-
ket could be collated into four major categories: Weight
loss products, energy/sexual enhancers, body/muscle
building and multivitamins.
Furthermore, interviewees outlined several triggers of
consumption of CAM products, the most important of
which were: loss of hope for a cure using orthodox
medicine; frustration with side-effects of orthodox medi-
cine; the relatively simpler use and lower cost of CAM
products (no medical prescription needed, no doctor’s
fee and CAM products could be delivered to one’s
door); perceived benefits of CAM products since they
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pagated by media sources.
Critique of current regulation
The “critique of current regulation” theme summarizes
the CAM stakeholders’ perspectives on the regulation of
CAM products and includes three main sub-themes: the
entry venues of CAM products into the market, the
review process, and the selling processes of CAM pro-
ducts in the Lebanese market.
Most stakeholders agreed that the CAM sector in
Lebanon is poorly regulated. This is not only due to the
lack of policies, procedures and regulations, but also due
to the chronic lack of adherence to existing regulations.
Originally, importers of CAM products had to pledge
not advertise their products on television, to restrict
their sales in pharmacies and not to make any therapeu-
tic claims for these products. Yet, over time, and due to
multiple factors including the poor monitoring of the
CAM market and the poor compliance to regulation,
CAM products became difficult to regulate. This was
eloquently stated by one of the interviewed key infor-
mants:
“The law as it stands today is not the biggest pro-
blem; it is rather the compliance to existing regula-
tions and the need to update and strengthen these
regulations”
The product entry process
Interviewed stakeholders voiced a concern with the
poorly enforced entry process of CAM products into the
Lebanese market. The official steps for the entry of
CAM products to the Lebanese market are well docu-
mented, including: entry & review of samples, submis-
sion to review committee at the MOH, review of the
product by the expert committee at the MOH, and
finally registration or rejection of the product. Yet,
according to stakeholders, poor adherence to the docu-
mented MOH policy coupled with loop holes in the reg-
ulations that restricts the entry of CAM products
through other venues, significantly eroded the effective-
ness of current regulation. Stakeholders stated the fol-
lowing entry venues for CAM products: through the
Ministry of Economics and Trade as food supplements;
with a special permission from the Minister of Health,
or by smuggling the product into the Lebanese terri-
tories. The quotes below demonstrate this point:
“What bothered us a lot is that we would decide on
forbidding certain products but the Minister would
still allow them.”
“Things are entering from beneath the table and
above the table. Who is responsible? No one is!”
The review process
Interviewees were divided on whether the review
requirements are enough and whether laboratory ana-
lyses might be necessary. For many, proper regulation of
CAM products is necessarily correlated with laboratory
testing because it would be the only way to assure the
content of the products entering the market. Concerns
were expressed over changing the labels of the products
that were refused on a first review and submitting them
again for a second review; using the words of one of the
interviewed stakeholders:
“The system was imperfect indeed. Sometimes we dis-
covered that certificates/labels presented to us were
fake and that companies did not exist.”
A number of stakeholders also pinpointed that the
CAM review process could be strengthened by revising
the membership of the CAM review committee to
include members that have better expertise in the field
of CAM.
The selling process
A consensus was reached among stakeholders that the
selling practices are rather erratic and in urgent need of
regulation and control. The current status quo is not
conducive to consumer protection. For example, as
expressed by one of the interviewees:
“Some products might be good products but adver-
tised for in the wrong way and sold for the wrong
reasons.”
Furthermore, interviewees agreed that there is no con-
trol on the market pricing of CAM products and that the
price of some products is unjustifiably high. It was also
established that each importer sets the price they desired
for their products with no governmental control and that
some products are seriously overpriced because of the
costs of advertising. One might think that, according to
basic economics, the higher price of the product would
decrease its demand, yet this is not the case in Lebanon.
This is primarily because consumers are led by intense
advertising to think that higher priced products are more
beneficial. The quote below highlights this issue:
“Although their prices are high, when people see
something on TV and when you tell them it is expen-
sive, then they think it is better”
Alameddine et al. BMC Complementary and Alternative Medicine 2011, 11:71
http://www.biomedcentral.com/1472-6882/11/71
Page 6 of 10There was also disagreement as to which authority
should ideally regulate the pricing of CAM products. A
number of stakeholders believe that product pricing
should be the responsibility of the MOH while others
designated the Ministry of Economics as the decision
maker in terms of pricing.
Barriers to proper regulation/integration
Thematic analysis of stakeholders’ responses revealed a
number of concerns related to the barriers which are
impeding the proper regulation and integration of CAM
products in the Lebanese market. These barriers are
categorized under five main sub-themes: weak infra-
structure, poor regulation, negative role played by poli-
tics, weak public/provider awareness and sub-optimal
coordination and cooperation among stakeholders.
With respect to infrastructure, one of the major lim-
itations in scaling up the control, regulation and integra-
tion of CAM products is the absence of a central
laboratory and hence, the absence of resources to test
the products that are entering the market. In addition, a
database for approved CAM products is nonexistent due
to the shortage of human resources at the MOH and
the general lack of required expertise in Lebanon. This
makes the analysis and follow-up on these products
beyond the capabilities of the current regulatory bodies.
Regulatory issues highlighted by stakeholders relate to
the limited power delegated to the expert committee,
w h o s ed e c i s i o n sa r ea d v i s o r ya n dn o tb i n d i n g .T h i s ,
added to the multiple entry points of CAM products,
has caused gradual erosion in the leverage of decision
making for the CAM expert committee. The diversity of
entry means has also made it difficult to assign responsi-
bility and accountability for the safety of the products
sold in the market. Many stakeholders expressed con-
cerns that products that were refused entry into the
market by the expert committee, products that were
u n d e rr e v i e wo rt h o s et h a tw e r en e v e rr e v i e w e d ,w e r e
all being sold in the market; According to one intervie-
wee:
“I once saw a product that was still under review on
the shelf of a pharmacy. In the review, I found that it
contains laxatives and should not be granted entry
into the market”
Such violations have eroded the trust of various stake-
holders in the credibility of the committee and have also
negatively influenced the commitment of committee
members.
There were recurrent calls to review the terms of
reference and empower the ‘CAM expert committee’.
Interviewees also shared that it should be the preroga-
tive of the committee to regulate the selling points of
products and be able to implement this decision on the
ground. Quoting one interviewee:
“The MOH should give the committee full liberty to
come up with independent decisions that are
BINDING.”
Interviewed stakeholders also described the negative
role played by politics as a major obstacle in the regula-
tion and integration of CAM products. Issues high-
lighted under this theme ranged from the general lack
of political will by the government to enhance the regu-
lation of this sector, to concerns about corruption, brib-
ery and favoritism, and finally, to the political protection
of some distributers of CAM products. Last but not
least, stakeholders’ described the negative role played by
some media outlets; most of which were politically
affiliated. For example one interviewee stated that:
“No one will stand up against the media. No one
dares to do that”
Further hindering the integration of CAM into the
Lebanese healthcare system was the poor awareness of
b o t ht h ep u b l i ca n dt h eh e a l t h c a r ep r o v i d e r so fC A M
products. Stakeholders described an unfortunate situa-
tion were reliable information about CAM products was
virtually non-existent for consumers. According to sta-
keholders, Lebanese CAM consumers often faced the
dual disadvantage of misleading advertisements and the
poor CAM literacy among healthcare providers. One of
the interviewed stakeholders summarized the situation
by saying:
“Unfortunately, we are in a country where there is no
awareness of CAM”
Stakeholders attributed the providers’ poor knowledge
of CAM to the lack of integration of CAM education
and training into the medical curricula and professional
education programs. The quote below highlights this
point:
“Physicians need education, they need to know
exactly what CAM products exist (in the market),
what has adverse effects. Such knowledge does not
currently exist among physicians”
Last but not least, interviewed stakeholders expressed
concern over the general lack of communication and
coordination among the various stakeholders in the
CAM market. The main identified stakeholders were the
Ministry of Health, Ministry of Economics and Trade,
Ministry of Interior, Ministry of Media, Consumer
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physicians, academic institutions, distributers and media
outlets. According to many interviewees, there was little
or no collaboration between stakeholders on the regula-
tion of the CAM market. To rectify the situation, a
number of stakeholders suggested the establishment,
under the patronage of the Ministry of Health, of a
national CAM coordinating committee on which all sta-
keholders would be represented. Furthermore, the need
to strengthen the role of consumer protection agencies
was highlighted. The two quotes below demonstrate the
view point of interviewees:
“Allocating a bigger role to consumer protection
offices would allow splitting tasks in a way that
would avoid any conflict of interest”.
“Consumer protection associations need to be more
pro-active...taking the lead of a centralized office for
complaints and should carry out post-market entry
follow up.”
Discussion
A key decision that Lebanon and other countries in the
EMR region have to make in the regulation of CAM
markets is the degree of public involvement in such reg-
ulation. The current study unearthed a number of impe-
diments that are decreasing the efficiency and
effectiveness of the regulation of CAM products in
Lebanon. Such impediments are consequently leading to
uninformed or unsafe public consumption of these pro-
ducts and are hindering the integration of CAM thera-
pies into mainstream medicine. Yet, Lebanon is not
alone in facing these regulatory hurdles.
In 2005, the World Health Organization (WHO) sur-
veyed EMR countries with respect to the national pro-
grams they have in place to regulate CAM products.
Surveyed EMR countries exhibited a wide variance
regarding the structure and comprehensiveness of the
policies, laws and regulations on CAM products. Per-
haps most telling about the poor regulatory capacity was
that fact that only a third of the surveyed EMR coun-
tries had a formal coordinating body for review and reg-
ulation of CAM/Traditional Medicine products [26].
Furthermore, the fragmented healthcare systems in
these countries and the lack of cooperation and infor-
mation sharing between the different ministries of
health contributed to the slow progress in developing
national policies that facilitate the integration of CAM
[37].
We believe that our overview of regulatory mechan-
isms in Lebanon, coupled with the stakeholders’ inter-
views, revealed that voluntary instruments and self
regulation are indeed disfavored as they are not viewed
as instruments conducive to proper regulation of the
CAM market in the country. This could be attributed to
t h ep o o ra w a r e n e s so ft h ep u b l i co nt h es a f eu s eo f
CAM products, coupled with the lack of proper knowl-
edge of healthcare providers on how CAM products
could be integrated into the treatment protocols of their
patients.
A careful synthesis of stakeholders’ responses reveals
an overall inclination to adopt a combination of mixed
and compulsory policy instruments [22]. Specifically,
stakeholders spoke about the need to enhance the
awareness of both the public and the providers on the
safe consumption of CAM products (a mixed policy
instrument), as well as the endorsement of a stricter
governmental regulation of the CAM sector (compul-
sory instrument). Note that while interviewed stake-
holders recommended stricter governmental regulation
of CAM products, none endorsed the adoption of the
stringent review and approval processes that are applic-
able to OTC products in Lebanon (they are dealt with
as pharmaceuticals).
According to stakeholders, strengthening the existing
CAM regulatory mechanisms requires the reorganiza-
tion of the sector to ensure a stronger governmental
control through better safety and efficacy testing.
Decrees, laws and legislations are indeed necessary but
not sufficient for the proper regulation of the market for
CAM products. Regulations need to be supplemented by
effective implementation, proper awareness and control.
The role of the MOH in organizing and regulating the
market for CAM products could indeed be strengthened
by using a systematic approach to drug regulation
through the drafting and lobbying at the parliament for
the passage of a national drug policy. Other suggestions
that could potentially enhance CAM products’ regula-
tion include: establishing and empowering a new CAM
expert committee; creating a comprehensive publically
accessible database for CAM products approved for sale;
ensuring (in collaboration with the Ministry of Media)
the monitoring of media outlets’ compliance with the
guidelines for CAM advertisement; and leading aware-
ness campaigns to promote safe consumption.
Two remarks are noteworthy regarding the above
mentioned stakeholders’ recommendations. The first is
that most are in conformity with the ones previously
published in WHO report [26,38,39]. The second relates
to the applicability of many of the above recommenda-
tions to other EMR countries, who face comparable reg-
ulatory, legal and organizational challenges. For
example, according to WHO, even when regulatory
bodies existed in EMR countries, their functionality and
effectiveness is dubious and is not necessarily conducive
to integrating these products into the main stream
healthcare system [26].
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awareness amongst both consumers and professionals
was highlighted as a mixed policy instrument that could
enhance the development and regulation of the market
for CAM products. It is a shared responsibility among
both public and private authorities (e.g. consumer pro-
tection agency, syndicates and orders) to educate the
public on the safe and effective consumption of CAM
products. This could be operationalized through the
organization of awareness campaigns, publishing an
annual inventory of approved and safe products in a
printed and electronic format, and dedicating a hotline
to provide consumers with information on the safe con-
sumption of CAM products.
Another mixed policy instrument that deems a close
collaboration and coordination between the public and
private sector is the integration of CAM into the medi-
cal and nursing curricula, as well as the establishment of
new training programs for CAM product specialists.
Such curricular review and redesign efforts should be
supplemented by a professional development programs
aiming at educating practicing professionals (e.g. physi-
cians, nurses, dietitian, pharmacists, etc.) on the safe
and effective use of CAM products.
A number of shortcomings in this manuscript are
worth mentioning. First, although every effort has been
exerted to ensure that the stakeholders are well repre-
sentatives of the CAM market, a stronger voice for con-
sumers and for the less visible community stakeholders
(not known to the authors) would have been preferred,
yet was not possible with the snowball sampling techni-
que. Second, it cannot be guaranteed that stakeholders’
own impressions and biases were excluded from the
analysis. Yet, the authors tried to minimize such biases
through identifying recurrent themes or by asking stake-
holders to provide evidence for certain dubious state-
ments. Note that extra caution was exerted when
analyzing the answers of the stakeholders who have
served as CAM expert committee members (three out
of sixteen) in order to ensure that their answers are not
self serving. Third, triangulation of the identified themes
with a thorough and contextual literature review could
have strengthened the validity of the findings, yet the
scarcity of literature on the regulation and integration of
C A Mp r o d u c t si nt h eE M Rr e g i o nd i dn o ta l l o wf o r
this. Finally, three of the identified stakeholders did not
agree to participate due to personal or professional rea-
sons, it could not be verified whether these stakeholders
hold points of view that might be different from those
that agreed to an interview.
Conclusions
Public regulation of markets is no easy task. The diver-
sity of policy instruments and regulatory schemes
available at the discretion of policy makers, coupled
with the lack of understanding of such schemes and
weak public infrastructure, further impedes proper regu-
lation in the EMR region in general, and Lebanon in
particular.
Although the MOH is identified as the stakeholder
playing a dominant role in CAM market regulation and
licensing, proper regulation remains a shared responsi-
bility among all stakeholders. The role of the MOH in
organizing and regulating the market for CAM products
could be strengthened through a combination of mixed
and compulsory policy instrument, including: initiating
the drafting of supporting legislations, streamlining the
entry and review processes for CAM products, and
spearheading public awareness initiatives.
Some of the identified impediments to proper regula-
tion of CAM markets and identified policy instruments
might be specific to the Lebanese context, yet many
would certainly apply to other EMR countries. The
authors acknowledge that the corrective measures and
ideas suggested in this manuscript will not happen over-
n i g h tn o rw o u l dt h e yh a v et ob ea l li m p l e m e n t e d .Y e t
progress would be made if such recommendation could
be integrated into a national drug policy, endorsed by
all concerned stakeholders, and supported by a clear
plan of action. Such a policy would aim at enhancing
public safety and well-being through the proper regula-
tion and integration of CAM products into healthcare
system. Political resolve coupled with the support of all
stakeholders, would be prerequisites for the success of
current and future regulation and integration attempts.
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